These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 39247806)

  • 1. Anti-TNFR2 Antibody-Conjugated PLGA Nanoparticles for Targeted Delivery of Adriamycin in Mouse Colon Cancer.
    Li P; Yang Y; Wang Y; Zheng J; Chen F; Jiang M; Chou CK; Cong W; Li Z; Chen X
    Research (Wash D C); 2024; 7():0444. PubMed ID: 39247806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
    Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFR2 deficiency impairs the growth of mouse colon cancer.
    Li P; Yang Y; Yang X; Wang Y; Chou CK; Jiang M; Zheng J; Chen F; Chen X
    Int J Biol Sci; 2023; 19(4):1024-1035. PubMed ID: 36923938
    [No Abstract]   [Full Text] [Related]  

  • 4. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
    He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
    Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
    Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
    Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.
    Nie Y; He J; Shirota H; Trivett AL; Yang D; Klinman DM; Oppenheim JJ; Chen X
    Sci Signal; 2018 Jan; 11(511):. PubMed ID: 29295954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model.
    Jing Q; Wan Q; Nie Y; Luo J; Zhang X; Zhu L; Gui H; Li L; Wang C; Chen S; Wang M; Yuan H; Lv H; Pan R; Jing Q; Nie Y
    Front Pharmacol; 2023; 14():1286061. PubMed ID: 38161697
    [No Abstract]   [Full Text] [Related]  

  • 9. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
    Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
    Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
    Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
    Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
    Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment.
    Chen X; Wu X; Zhou Q; Howard OM; Netea MG; Oppenheim JJ
    J Immunol; 2013 Feb; 190(3):1076-84. PubMed ID: 23277487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4
    He T; Liu S; Chen S; Ye J; Wu X; Bian Z; Chen X
    Front Immunol; 2018; 9():1556. PubMed ID: 30038619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer.
    Fu Q; Shen Q; Tong J; Huang L; Cheng Y; Zhong W
    Front Cell Dev Biol; 2021; 9():720472. PubMed ID: 34900985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.
    Chen X; Hamano R; Subleski JJ; Hurwitz AA; Howard OM; Oppenheim JJ
    J Immunol; 2010 Jul; 185(1):174-82. PubMed ID: 20525892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
    Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
    J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
    Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
    BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
    Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
    BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.